AzTrials
AzTrials

HEART FAILUREHEFESTOSNCT02444676

Heart Failure STratification and OutcomeS

An observational study of HEART FAILURE, run by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Heart failure (HF) is in many cases the final way for coronary heart diseases. In older than 65 years is the most important cause of hospitalization. Many studies have analyzed the causes of decompensation and the possible causes of hospital re-admission but most evidences come from the hospital setting. Read more about this study

Who is it for?
Ages 45 years and older
Conditions the study is for
HEART FAILURE
What is being tested?
Stratification and outcomes
How many people
560 participants
Where
1 siteSpain
Study dates
Mar 2015to Dec 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Heart Failure patients included in the study will come from primary care setting. We consider primary care, the health assistance provided in outpatients by a General practitioner, or out of hours care in primary care setting.

Who may be able to join

None listed.

Who cannot join

  • Patients with severe psychiatric illness or severe cognitive impairment, not able to complete the study protocol.
  • Refusal to participate in the study.
  • Patients directly attended in the hospital in the previous 30 days.
  • Every patient will be followed up to 30 days after the decompensation episode. We are intended to consecutively including patients in the study during a period of two years, from December 2014 to December 2016.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Institut Català de la Salut

    Barcelona

Other trials in Spain

About this study

Background: Heart failure (HF) is in many cases the final way for coronary heart diseases. In older than 65 years is the most important cause of hospitalization. Many studies have analyzed the causes of decompensation and the possible causes of hospital re-admission but most evidences come from the hospital setting. Nevertheless, It is known that many of these patients are usually attended in primary care setting, being treated by their General Practitioner and are not referred to the hospital.

The determinants which condition whether stable HF patients will be hospitalized as a consequence of a decompensation remain still unclear.

Read more

Objective: To develop and validate a predictive model based on clinical variables easy to measure at primary care to predict short-term hospitalization or mortality in a cohort of patients attended in primary care setting as a consequence of a HF decompensation.

Methods: A cohort of patients with established HF attended in primary care setting (regular care or out of hours) as a consequence of an episode of HF decompensation will be follow up. To develop the predictive model we will select variables which previously have been found involved in the risk of hospitalization or mortality as a consequence of HF as well as other ones which could be relevant and have not been studied yet. Variables selected should be easily determined in primary care setting..

The predictive model obtained in the derivation cohort from Spain will be validated in an external (several European countries) validation cohort.

Relevance: Our study will help GP to identify HF patients at higher risk of hospitalization or death and manage them according to an accurate prognostic rule (escala pronostica) made in primary care setting.[DISCUTIR]

Read the detailed description

DESIGN:

Multicenter prospective cohort study in which patients diagnosed of Heart Failure and suffering from a clinical decompensation will be followed for a 30 days in order to predict short-term hospitalització or mortality.

SETTING:

  1. Derivation cohort will consist of HF patients recruited in more than 20 general practices settled in the city of Barcelona.
  2. Internal validation cohort: population recruited will come from the same general practices than derivation cohort.
  3. External Validation population will come from the rest of European countries participants.

Since the health system could be different in the participant countries we will consider as a primary care all consultations attended by General Practitioners out of the hospital setting (which includes out of hours clinics managed by GP).

Previous versions of this protocol have been presented to two European networks: Euroohnet (European research network in out of hours) and EGPRN (European General Practice Research Network).

In order to be able to generalize the results to the European territory, all European countries would be invited to participate. Up to data, Barcelona (Spain), France, Slovenia, Ireland, Italia, Turkey and Portugal have accepted to participate.

RECRUITMENT

Participants will be consecutively recruited from September 2014 to September 2016, amongst those previously diagnosed from HF who need to be attended in primary care from a clinical decompensation Study protocol will be previously presented to all potential GP participants and a hard copy will be distributed to all of them as well as informed consents to be signed by the patients who accept to be included. In this protocol all the instructions regarding recruitment, inclusion criteria, measurements and follow up will be written. GP participants must agree with the study protocol, and to consent to participate and to provide necessary data from their patients.

Since it is an observational study no randomization will be needed. Recruitment will end when the sample size is raised.

STUDY POPULATION

Heart Failure patients included in the study will come from primary care setting. We consider primary care, the health assistance provided in outpatients by a General practitioner, or out of hours care in primary care setting.

Inclusion criteria:

Patients aged 45 or more with previous diagnoses of HF in its medical record and a decompensation of HF treated/attended in primary care settings at the moment of the inclusion.

Decompensation is defined as the presence of at least one of the following clinical conditions (12):

  • The worsening functional class according to the criteria of the New York Heart Association (NYHA).
  • A weight gain of more than one kilogram in a period of 24 hours or greater than two kilograms in a maximum of 72 hours.
  • Increased ankle edema (self-reported by the patient, caregiver or physician)

Exclusion criteria:

  • Patients with severe psychiatric illness or severe cognitive impairment, not able complete the study protocol.
  • Refusal to participate in the study.
  • Patients directly attended in the hospital in the previous 30 days.

Every patient will be followed up to 30 days after the decompensation episode. We are intended to consecutively including patients in the study during a period of two years, from December 2014 to December 2016.

DATA COLLECTION: Procedures, measurements and Instruments

Sources of information

Variables will be obtained by:

  • Interview to the patients
  • Clinical exploration
  • Primary medical record
  • Hospital discharge reports. We will create a specifically designed questionnaire for the study where will registry information about personal medical history, clinical examination at the moment of the visits. These data will be supplemented with information from primary care electronical medical records.

Once the patient has signed the informed consent we will proceed to obtain the variables and measurements for the study.

In the final database only an identification number should be available for each patient. This ID should be easily associated with the data of patient, but only by their GP. Identification of patients should not be allowed to the rest of researchers. Every GP participant will have a list with their patients included in the study.

The ID will be as follows:

Country: SP (Spain), FR (France), PO(Portugal), TU (Turkey)…….. Surname of the GP responsible for the patient (initial) Date of birth of the patient (day/month/year) (--/--/----) ID number labeled by the main researcher of each country.

The coordinator centre (.Institut Català de la Salut. IDIAP-Jordi Gol, Spain) will design an electronic on-line questionnaire (https://es.surveymonkey.com/) which will be hosted in the website of IDIAP-Jordi Gol: (http://www.idiapjgol.org/) and e-mailed to all of GP participants in the study.

Potential predictive variables:

  • Age (years)
  • Gender
  • Personal medical history (information obtained from medical record or interview) as dichotomous variables:

Diabetes mellitus ( ICD 10: E10, E11, E12, E13, E14) (YES/NOT) History of cardiovascular diseases (CHD or stroke) (ICD 10: I20-125; I63-I66) (YES/NOT) Chronic Kidney disease (ICD 10 N18) (YES/NOT) Current smoking (ICD 10: F17.1) (YES/NOT) Chronic Obstructive Pulmonary Disease (ICD 10: J43, J44) (YES/NOT) Previous hospital admission as a consequence of HF in the last year (YES/NOT)

  • Clinical exploration at the baseline visit (decompensation episode) NYHA (III-IV vs I-II) (YES/NOT) Crackles (YES/NOT) Heart rate: beats/min Respiratory frequency Body Mass Index (to register weight and height) : km/m2 Temperature (ºC) Bilateral ankle edema with fovea (YES/NOT) ECG : Normal, Atrial fibrillation, Branch block, Acute Ischemia, Other arrhythmias Systolic Blood pressure : mmHg Diastolic Blood pressure: mmHg Treated with furosemide (a)/torasemide (b) before the visit : mg/day Not 1-40 mg (a) or 5mg (b) 40-80mg(a) or 5-10mg (b) >= 80 mg(a) or >10mg(b)

Other possible causes of decompensation:

  • Dietary sodium excess: supplementation with salt to the aliments : (YES/NOT)
  • Compliance with drugs : (YES/NOT)
  • Excessive liquid intake: taking >2, 5 l/day
  • Suspected Respiratory infection: (YES/NOT)
  • Suspected other infections (YES/NOT)
  • Known anemia (YES/NOT)

Others (By interviewing):

  • Time since the first symptoms: hours
  • Paroxistic dispnea: (YES/NOT)
  • Weight gaining in the last week (self perceived) : (YES/NOT) 10. Data of diagnostic of HF (ICD 10: I.50) in medical record. 11. Setting of assistance:
  1. Regular care (usual GP)
  2. Out of hours care
  3. At home
Conditions
HEART FAILURE
Being tested
Stratification and outcomes
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Stratification and outcomesOther

    Also called observational study

    No necessary

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hospital admission

    Hospital admission during the following 30 days as a consequence of the episode of decompensation. (We will consider hospital admission a stay at hospital > 24 hours.)

    Measured: 30 days

  2. Mortality

    Mortality during the first 30 days after the episode of decompensation (at home or at the hospital).

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2015 (estimated)
  2. Study startMar 2015
  3. Primary completionSep 2019
  4. Study completionDec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
560 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02444676
Sponsor's protocol ID
PI 00269
Acronym
HEFESTOS
Status last verified
Feb 2021
First submitted
12 May 2015
Last updated
5 May 2022
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of HEART FAILURE, run by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hospital admission (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in